Latest Governance News

Vintage Energy has launched a $2.1 million equity entitlement offer to fund drilling two new gas wells, supported by a South Australian government grant, and to advance oil exploration in the Cooper Basin.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Genesis Energy has successfully completed a NZ$300 million rights offer, with strong shareholder participation including the Crown maintaining its majority stake. The capital raise underpins the company’s Gen35 strategy and sets the stage for upcoming share trading.

Triton Minerals advances the sale of a majority stake in its Mozambique graphite assets pending government approval, while assay results from its AuCu Gold-Copper drilling program remain delayed due to lab backlogs.

Vita Resources has secured a pivotal recommendation from Yukon authorities to proceed with a five-year exploration program at its ICE Copper-Gold Project, marking a significant step forward in its Canadian mining ambitions.

Merino & Co. Limited has attributed the late lodgement of director interest notices to an administrative oversight and reaffirmed its compliance measures to meet ASX disclosure rules.

Almonty Industries has commenced commercial production at its flagship Sangdong Mine in South Korea and secured more than US$200 million through Nasdaq IPO and equity offerings to fund expansion projects. Despite rising revenues driven by soaring tungsten prices, the company reported a significant net loss due to non-cash derivative liabilities.

SunRice Group maintains its forecast for profit growth in FY26, even as revenue is expected to remain flat or slightly decline due to competitive pressures, adverse weather, and geopolitical disruptions.

Sarytogan Graphite Limited has received over $2 million from key investor Dias Sarsenov, advancing its share placement strategy and preparing for a pivotal board appointment. Meanwhile, a significant top-up investment from the EBRD awaits shareholder approval.

Diatreme Resources has reported a significant boost in mineral recoveries and production forecasts for its Cyclone Project in Western Australia, driven by advanced metallurgical testwork and flowsheet optimisation.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

Magnetite Mines Limited’s MGTOG securities have been suspended from ASX quotation due to non-compliance with listing rules, raising questions about the company’s regulatory standing.